Lynsight

Lynch syndrome is one of the most common hereditary cancer syndromes, yet too often it goes undiagnosed until a serious health issue emerges.

A growing body of research, including recent findings published in Clinical Gastroenterology and Hepatology, makes a strong case for universal Lynch syndrome screening. This proactive approach could lead to earlier detection, better outcomes, and lasting benefits for patients, families, and healthcare systems alike.

Read the full blog to learn why now is the time to make universal screening the standard: https://lynsightlabs.com/why-universal-lynch-syndrome-screening-matters/

At Lynsight, we recognize World Pancreatic Cancer Day as a vital opportunity to raise awareness, promote early detection, and stand in solidarity with those affected by this disease.

Pancreatic cancer is one of the most aggressive cancers, with genetics playing a significant role in some cases, including those related to Lynch syndrome. Early detection can make all the difference, which is why awareness and education are so critical.

Whether you're honoring a loved one, raising awareness, or advancing research, your voice matters. Together, we can make early detection and better outcomes possible.

See how Lynsight is leading the way in early cancer detection: https://lynsightlabs.com/lynch-syndrome-testing/

On September 30, came together for our Fall Quarterly Meeting at the stunning Haikko Manor in Porvoo, Finland. Surrounded by history and inspiration, we reconnected, reflected, and recharged our mission to advance Lynch syndrome research and innovation.

We’re excited for what’s ahead! Follow our journey as we continue driving discovery and impact for Lynch sydrome! 🧡

Read more about our impactful team meeting: https://lynsightlabs.com/lynsights-fall-quarterly-meeting-a-memorable-blend-of-insight-and-team-spirit-at-haikko-manor/

We’re proud to announce our strategic partnership with New Day Diagnostics, a leading innovator in diagnostic solutions, to initiate clinical studies and accelerate U.S. market access for DiagMMR, our proprietary diagnostic test for identifying mismatch repair deficiencies, the key biomarker in Lynch syndrome.

This milestone marks a major step in our mission to expand access to advanced diagnostics and improve early detection of hereditary cancer syndromes. Together, we’re combining clinical validation, research infrastructure, and shared expertise to bring DiagMMR to healthcare providers and patients across the U.S.

Clinical studies are set to begin in early 2026 with top-tier U.S. institutions, paving the way for FDA authorization and nationwide impact.

Read the full press release to learn more about the partnership: https://lynsightlabs.com/lynsight-announces-strategic-partnership-with-new-day-diagnostics-to-advance-diagmmr-clinical-studies-in-the-united-states/

Early detection saves lives.

Lynch syndrome is one of the most common inherited conditions, and often goes undiagnosed.

By prioritizing preventative health and genetic testing, we can identify risk early and take action before cancer develops.

Learn more about the impact of Lynch syndrome testing → https://lynsightlabs.com/lynch-syndrome-testing/